
Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk, R/R CLL
Lisocabtagene maraleucel (liso-cel; Breyanzi) generated durable responses and extended survival in patients with heavily pretreated, high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had …